Study of Efficacy and safety with golimumab in the treatment of children’s rheumatic diseases

study of golimumab in the treatment of rheumatic diseases with children

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033582

Enrollment

Unknown

Registered

2020-06-06

Start date

2020-06-05

Completion date

Unknown

Last updated

2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatic diseases in children

Interventions

experimental group:golimumab IH

control group:Oral traditional medicine

Eligibility

Sex/Gender

All

Age

1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. According to the international diagnostic guidelines and recommendations, children with rheumatic diseases, including juvenile idiopathic arthritis, juvenile dermatomyositis, vasculitis, etc. 2. Patients who are not well treated with traditional medicine or who agree to use golimub according to the wishes of their families.

Exclusion criteria

Exclusion criteria: 1. Patients with acute infection. 2. Patients with latent tuberculosis and / or hepatitis B virus infection.

Design outcomes

Primary

Measure	Time frame
thrapy effect;side effect;	—

Countries

China

Contacts

Public ContactChen Xiangyuan

Guangzhou Women and Children's Medical Center

very88happy@163.com+86 18198915321

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026